No, only beriberi is definitively treatable with thiamine—IBS, IBD, and SIBO are not established thiamine-responsive conditions.
Thiamine (vitamin B1) is FDA-approved specifically for the treatment of beriberi and thiamine deficiency states, not for IBS, IBD, or SIBO as primary conditions 1.
Beriberi: Clear Indication
Thiamine is the definitive treatment for beriberi, whether "dry" (neurologic) or "wet" (cardiovascular) forms 1. The FDA label specifies:
- 10-20 mg IM three times daily for up to 2 weeks for beriberi treatment
- 25 mg IV cautiously for infantile beriberi with collapse
- 100 mg IV initially, then 50-100 mg IM daily for Wernicke-Korsakoff syndrome 1
This is straightforward: if beriberi is diagnosed, thiamine is the treatment.
IBD: Limited Evidence for Fatigue Only
For inflammatory bowel disease, thiamine is not a treatment for the disease itself. However, one high-quality RCT showed that high-dose oral thiamine (600-1800 mg/day based on gender and weight) significantly reduced chronic fatigue in patients with quiescent IBD 2. This 2021 crossover trial demonstrated:
- Mean fatigue reduction of 4.5 points with thiamine vs. 0.75 point increase with placebo (p=0.0003)
- 55-75% of patients showed clinically meaningful improvement (≥3 points)
- Well-tolerated with only mild side effects
Critical caveat: This addresses fatigue as a symptom in patients with already-controlled IBD, not the inflammatory disease process itself. Current AGA guidelines for IBD nutritional management emphasize monitoring for vitamin D, iron, and B12 deficiency (especially with ileal disease), but do not recommend routine thiamine supplementation 3.
IBS: Emerging Genetic Evidence, No Clinical Recommendation
For irritable bowel syndrome, the evidence is preliminary and mechanistic rather than therapeutic:
- A 2026 GWAS study identified genetic variants in thiamine metabolism (SLC35F3 and XPR1) that modulate stool frequency, with dietary thiamine intake positively associated with bowel movement frequency 4
- A 2006 case-control study showed symptom improvement with a multi-ingredient supplement containing B vitamins (including B1), but this was not thiamine alone and the study quality was limited 5
The 2022 AGA Clinical Practice Update on diet in IBS makes no mention of thiamine supplementation 6. The guideline emphasizes low-FODMAP diets and referral to registered dietitians, not vitamin supplementation.
SIBO: No Role for Thiamine
Small intestinal bacterial overgrowth is treated with antibiotics (primarily rifaximin) and dietary modifications 7, 8. A 2026 meta-analysis confirmed rifaximin achieves 59% SIBO eradication rates, with medium-to-high doses (≥1,200 mg/day) showing superior efficacy 8.
Thiamine has no established role in SIBO treatment. While a 2025 review discusses theoretical mechanisms linking thiamine to gastrointestinal motility and acetylcholine signaling 9, this remains speculative without clinical trial evidence.
Clinical Algorithm
When considering thiamine for gastrointestinal conditions:
Beriberi suspected (cardiac symptoms, neuropathy, nutritional deficiency risk factors)?
- YES → Administer thiamine immediately per FDA dosing 1
IBD patient with severe chronic fatigue despite disease control?
- Consider trial of high-dose oral thiamine (600-1800 mg/day) for 4 weeks 2
- Monitor for symptom improvement
- This is adjunctive for fatigue, not disease treatment
IBS or SIBO diagnosis?
Important Pitfalls
- Do not delay appropriate treatment for IBS or SIBO by attempting thiamine supplementation
- Do not confuse gastrointestinal symptoms of beriberi (which can include dysmotility) with functional disorders like IBS
- Thiamine deficiency can occur in IBD due to malabsorption, but routine screening is not currently recommended by guidelines (unlike vitamin D, iron, and B12) 3